Evotec stock heads into the open after a new 52-week low
Published on 09/15/2026 at 08:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock closed at EUR 2.86 on Xetra on September 14, 2026, down about 3.6% from the prior session and marking a new 52-week low. In the same session the shares traded between roughly EUR 2.86 and EUR 2.97, while the MDAX index held near 31,143 points, leaving Evotec clearly weaker than its home benchmark.
September 14, 2026 in numbers
Evotec SE (ISIN DE0005664809) came under renewed selling pressure in Xetra trading on September 14, 2026, where intraday reports showed the share price slipping to an intraday low around EUR 2.86 and testing a fresh 52-week low zone between EUR 2.86 and EUR 2.97. According to finanzen.ch data cited in a same-day market overview, the stock was down around 2.4% to EUR 2.90 at midday, with the MDAX near 31,187 points, before later Xetra indications pointed to a weaker end-of-day level around EUR 2.86 that translated into a loss of about 3.6% versus the previous close.
As Ad-hoc-news summarized on September 14, 2026, the share fell intraday to EUR 2.86, establishing the current 52-week low and leaving the price well below earlier closing levels around EUR 3.03 and far under analyst target ranges reaching up to EUR 10.00. In a separate commentary, Aktiencheck reported on September 14, 2026 that the shares were under pressure around EUR 2.894, down roughly 2.5%, while highlighting a short attack initiated by Y-Intercept (Hong Kong) as one factor weighing on sentiment. Taken together, the combination of a fresh 52-week low, short-selling interest and a clear underperformance versus the MDAX defined the trading profile of Evotec in the last completed session.
Today’s drivers to watch
Looking at today, September 15, 2026, investors face a backdrop in which Evotec recently attracted short interest and hit new 52-week lows on both its Xetra listing and its Nasdaq-traded shares. As MarketBeat noted on September 14, 2026, the Nasdaq-quoted Evotec share price touched a new 12-month low around USD 1.67 in the latest US session, underscoring the global nature of the recent weakness. In addition, a short-interest overview on MarketBeat updated in September 2026 pointed to thousands of shares sold short on the Nasdaq listing as of mid-August, a factor that can amplify moves when sentiment shifts. Against this backdrop of technical pressure and visible short positioning, any further analyst commentary, regulatory updates on Evotec’s development programs or sector-wide biotech news released today could influence trading once the next Xetra session gets under way.
